ZENDESK INC (ZEN)

US98936J1016 - Common Stock

77.48  +0.02 (+0.03%)

After market: 77.47 -0.01 (-0.01%)

Buy % Consensus

65

ChartMill assigns a Buy % Consensus number of 65% to ZEN. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 95.06. This target is 22.68% above the current price.
ZEN was analyzed by 19 analysts. The buy percentage consensus is at 65. So analysts seem to be rather neutral about ZEN.
In the previous month the buy percentage consensus was at a similar level.
ZEN was analyzed by 19 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target & Forecast

Price Low Median Mean High 77.4878.2879.0595.06168.00 - 1.03% 2.03% 22.68% 116.83%
Up and Down Grades
Date Firm Action Rating
2022-07-26 William Blair Downgrade Outperform -> Market Perform
2022-07-26 JMP Securities Downgrade Market Outperform -> Market Perform
2022-07-26 Stifel Downgrade Buy -> Hold
2022-07-18 Piper Sandler Maintains Neutral
2022-06-29 Craig-Hallum Downgrade Buy -> Hold
2022-06-28 Barclays Downgrade Overweight -> Equal-Weight
2022-06-27 Barclays Downgrade Overweight -> Equal-Weight
2022-06-17 Evercore ISI Group Maintains In-Line
2022-06-13 Morgan Stanley Downgrade Overweight -> Equal-Weight
2022-06-10 Stifel Maintains Buy
2022-05-23 Jefferies Maintains Hold
2022-04-29 Piper Sandler Maintains Neutral
2022-02-14 Wolfe Research Downgrade Outperform -> Peer Perform
2022-02-11 Piper Sandler Maintains Neutral
2021-11-19 Cowen & Co. Downgrade Outperform -> Market Perform
2021-11-19 Credit Suisse Maintains Neutral
2021-11-19 Piper Sandler Maintains Neutral
2021-11-16 Credit Suisse Initiate Neutral
2021-10-29 Oppenheimer Downgrade Outperform -> Perform
2021-10-29 B of A Securities Downgrade Buy -> Neutral
2021-10-29 Piper Sandler Downgrade Overweight -> Neutral
2021-10-29 Jefferies Downgrade Buy -> Hold
2021-10-21 Barclays Initiate Overweight
2021-07-30 Piper Sandler Maintains Overweight
2021-04-23 Wolfe Research Initiate Outperform